8-K: Stryker Completes Acquisition of Inari Medical for $4.94 Billion

Stryker Corporation finalizes its acquisition of Inari Medical, Inc., marking the completion of a merger agreement initiated in January 2025.

Summary

• Stryker Corporation has completed its acquisition of Inari Medical, Inc.
• The acquisition was executed through a merger of Stryker's subsidiary, Eagle 1 Merger Sub, Inc., with Inari.
• The tender offer for Inari's shares expired on February 18, 2025, with approximately 81.69% of shares tendered.
• Stryker acquired all outstanding shares of Inari for $80.00 per share in cash, totaling approximately $4.94 billion.
• Inari Medical is now a wholly-owned subsidiary of Stryker.
• Inari's stock has been delisted from the NASDAQ Global Select Market.
• Compensatory stock options and restricted stock units were cashed out at the offer price.
• Inari's 2020 Incentive Award Plan, 2011 Equity Incentive Plan, and Amended and Restated 2020 Employee Stock Purchase Plan have been terminated.
• Inari's Loan, Guaranty and Security Agreement was satisfied and discharged in full, and the Credit Facility was terminated.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The acquisition provides a clear exit strategy for Inari shareholders and strengthens Stryker's market position. However, Inari will no longer operate as an independent entity.

Positives

• Shareholders received $80.00 per share in cash.
• Existing stock options and restricted stock units were cashed out at a premium.
• Stryker's acquisition provides Inari with greater resources and stability as a wholly-owned subsidiary.

Negatives

• Inari Medical is no longer a publicly traded company.
• Inari's stock has been delisted from the NASDAQ Global Select Market.
• Inari's 2020 Incentive Award Plan, 2011 Equity Incentive Plan, and Amended and Restated 2020 Employee Stock Purchase Plan have been terminated.

Risks

• Integration risks associated with merging Inari Medical into Stryker's operations.
• Potential for changes in Inari's operations, policies, or practices under Stryker's ownership.
• Uncertainty regarding the long-term impact of the acquisition on Inari's employees and stakeholders.

Future Outlook

Inari Medical will operate as a wholly-owned subsidiary of Stryker. The document does not provide specific forward-looking statements regarding Inari's future performance or integration plans.

Industry Context

This acquisition reflects a trend of consolidation in the medical device industry, where larger companies acquire smaller, innovative firms to expand their product portfolios and market reach. Stryker's acquisition of Inari Medical strengthens its position in the vascular intervention space.

Comparison to Industry Standards

• The acquisition multiple is within the typical range observed in the medical device industry for companies with innovative technologies and strong growth potential.
• Comparable acquisitions in the medical device space include Boston Scientific's acquisition of BTG plc and Medtronic's acquisition of Mazor Robotics.
• These acquisitions often involve a premium valuation based on the target company's intellectual property, market position, and growth prospects.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders received cash consideration for their shares.
• Employees may experience changes in their roles and responsibilities as Inari integrates with Stryker.
• Customers will continue to have access to Inari's products through Stryker's distribution network.
• Suppliers may need to adapt to Stryker's procurement processes.

Next Steps

• Integration of Inari Medical into Stryker's operations.
• Continued development and commercialization of Inari's products under Stryker's ownership.
• Filing of a Form 15 with the SEC to terminate registration of the Shares under Section 12(g) of the Exchange Act and suspend Inari's reporting obligations.

Key Dates

Keywords

acquisition, merger, Stryker, Inari Medical, tender offer, delisting